Intervention not reported
Placebo · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 59 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Daclizumab (Direct evidence; 1 RCT; 621 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention probably leads to lower daclizumab (Direct evidence; 1 RCT; 621 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Intervention (no. of studies/participants)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Interferon beta‐1b (Betaferon) (Direct evidence; 2 RCTs; 403 participants)
It is very uncertain whether the intervention changes interferon beta‐1b (Betaferon) (Direct evidence; 2 RCTs; 403… (very low certainty).
1 finding from 1 review
RR 0.86 [0.67, 1.11]
1 study · 2 participants
Very low
Intervention not reported
Placebo
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Fingolimod No direct evidence · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention probably leads to lower fingolimod No direct evidence (moderate certainty).
1 finding from 1 review
RR 0.48 [0.39, 0.57]
Studies not reported
Moderate
Intervention not reported
Glatiramer acetate (Direct evidence; 2 RCTs; 1454 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention may leads to lower glatiramer acetate (Direct evidence; 2 RCTs; 1454 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Immunoglobulins (Direct evidence; 2 RCTs; 91 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention probably leads to lower immunoglobulins (Direct evidence; 2 RCTs; 91 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Interferon beta 1a‐1b No direct evidence · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
It is very uncertain whether the intervention changes interferon beta 1a‐1b No direct evidence (very low certainty).
1 finding from 1 review
RR 1.42 [0.78, 2.6]
1 participants
Very low
Intervention not reported
Interferon beta‐1b (Betaferon) No direct evidence · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
It is very uncertain whether the intervention changes interferon beta‐1b (Betaferon) No direct evidence (very low certainty).
1 finding from 1 review
RR 0.82 [0.5, 1.33]
1 participants
Very low
Intervention not reported
Interferon beta‐1a (Avonex, Rebif) (Direct evidence; 1 RCT; 560 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention may leads to lower interferon beta‐1a (Avonex, Rebif) (Direct evidence; 1 RCT; 560… (low certainty).
1 finding from 1 review
Intervention not reported
Total studies: 47 Total participants: 4398 · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
47 participants
GRADE not reported
Intervention not reported
TXA given intra‐articularly at a total dose of 2 g intraoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
2 participants
Low
Intervention not reported
TXA given intravenously at a total dose of 1 g intraoperatively and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
TXA given orally at a total dose of greater than 3 g pre‐incision and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
3 participants
Very low
Intervention not reported
TXA given orally at a total dose of 2 g pre‐incision · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
2 participants
Low
Intervention not reported
TXA given intra‐articularly at a total dose of 1 g intraoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
TXA given intravenously at a total dose of greater than 3 g intraoperatively and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
3 participants
Moderate
Intervention not reported
TXA given intravenously and intra‐articularly at a total dose of 2 g pre‐incision and intraoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
2 participants
Very low